[Dkt. 9189]

Detroit Auto Dealers Association, Inc., et al.; Prohibited Trade Practices and Affirmative Corrective Actions

AGENCY: Federal Trade Commission.

ACTION: Modified Final Order.

SUMMARY: This order modifies an earlier Commission order to require, for one year, that the automobile dealership and dealership owner respondents involved in the proceeding open their showrooms for a minimum of 64 hours per week, or, at their option, to maintain minimum hours of operation of an average of ten and one half hours per day on weekdays, plus a minimum of eight hours on Saturdays. In addition, the Commission modifies Part VII.D of the Final Order, issued in 1989, by changing from 30 days to 60 days the time period within which the dealership association respondent must investigate and resolve allegations that association members have violated by-laws, rules, or regulations affected by the order.

DATES: Final order issued February 22, 1989. Modified final order issued June 20, 1995.[1]

FOR FURTHER INFORMATION CONTACT: Ernest Nagata, FTC/H–394, Washington, D.C. 20580. (202) 326–2714.

SUPPLEMENTARY INFORMATION: In the Matter of Detroit Auto Dealers Association, Inc., et al. The prohibited trade practices and/or corrective actions as set forth at 54 FR 14337, are changed in part.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interprets or applies sec. 5, 38 Stat. 719, as amended; 15 U.S.C. 45)

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 95–21161 Filed 8–24–95; 8:45 am]

BILLING CODE 6750–01–M

[1] Copies of the Order and the Opinion of the Commission, are available from the Commission's Public Reference Branch, H–130, 6th Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention (CDC)

Advisory Committee on Childhood Lead Poisoning Prevention: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Advisory Committee on Childhood Lead Poisoning Prevention.

Times and Dates: 8:30 a.m.–5 p.m., September 12, 1995; 8:30 a.m.–12 noon, September 13, 1995.

Place: Holiday Inn Atlanta—Peachtree Corners, 6050 Peachtree Industrial Boulevard, NW, Norcross, Georgia 30071.

Status: Open to the public, limited only by the space available.

Supplementary Information: In October 1991 the Secretary of Health and Human Services released the CDC policy statement ''Preventing Lead Poisoning in Young Children.'' This statement is used by pediatricians and lead screening programs throughout the United States, and great progress has been made in implementing the statement. Copies of this statement may be requested from the contact person listed below.

Matters to be Discussed

Since the release of this statement, new data have become available and some information gaps have been identified. The Committee will continue to discuss issues related to revising the statement, particularly the blood lead screening guidelines.

Agenda items are subject to change as priorities dictate.

Persons wishing to make written comments regarding additions or changes to the statement should provide such written comments to the contact person no later than September 5, 1995.

Opportunities will be provided during the meeting for oral comments. Depending on the time available and the number of requests, it may be necessary to limit the time of each presenter.

Contact Person for More Information: Barbara Nelson, Program Analyst, Lead Poisoning Prevention Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, (F42), Atlanta, Georgia 30341–3724, telephone 404/448–7330, FAX 404/488–7335.

Dated: August 17, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–21136 Filed 8–24–95; 8:45 am]

BILLING CODE 4163–18–M

National Committee on Vital and Health Statistics (NCVHS) Subcommittee on Health Statistics for Minority and Other Special Populations: Meeting

Pursuant to Pub. L. 92–463, the National Center for Health Statistics (NCHS), Centers for Disease Control and Prevention (CDC), announces the following subcommittee meeting.

Name: NCVHS Subcommittee on Health Statistics for Minority and Other Special Populations.

Time and Date: 8:30 a.m.–4:30 p.m., September 28, 1995.

Place: Room 503A–529A, Hubert H. Humphrey Building, 200 Independence Avenue SW., Washington, DC 20201.

Status: Open

Purpose: The subcommittee will investigate racial disparities among the insured population and will be briefed on the status of the Report to the Assistant Secretary on Socioeconomic Status and the Health of Americans. The subcommittee will review progress in the effort to improve racial and ethnic identification on the Social Security Administration and the Health Care Financing Administration's administrative records and results from the U.S. Census Bureau studies designed to evaluate the use of multi-racial categories in population surveys.

Contact Person for More Information: Substantive program information as well as summaries of the meeting and a roster of committee members may be obtained from Gail F. Fisher, Ph.D., Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, MD 20782, telephone 301/436–7050.

Dated: August 21, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–21138 Filed 8–24–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95N–0271]

Drug Export; Anzemet (Dolasetron Mesilate) Tablets 25 mg, 50 mg, 100 mg, 200 mg

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Marion Merrell Dow Inc., has filed an application requesting conditional approval for the export of the human drug Anzemet (dolasetron mesilate) Tablets to France for packaging and transshipment to the United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of

human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug Evaluation and Research, HFD–310 Food and Drug Administration, 7520 Standish Place, Rockville, MD 20855, 301–594–3150.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Marion Merrell Dow, Inc., Marion Park Drive, P.O. Box 9627, Kansas City, Missouri 64134–0627, has filed an application requesting conditional approval for the export of the human drug Anzemet (dolasetron mesilate) Tablets to France for packaging and transshipment to the United Kingdom. Anzemet is used for the treatment of nausea and vomiting induced by cancer chemotherapy, radiotherapy and post-operative nausea and vomiting. The application was received and filed in the Center for Drug Evaluation and Research on August 8, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by September 5, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec.and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food Research (21 CFR 5.44).

Dated: August 14, 1995.

Betty L. Jones,

Deputy Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 95–21094 Filed 8–24–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95D–0114]

Medical Devices; Premarket Notification (510(k)) Practices; Procedures/Good Manufacturing Practices/Compliance Program; Availability; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a document that announced the availability of revisions to the standard compliance program for good manufacturing practices (GMP's) (Compliance Program 7382.830). The document was published in the **Federal Register** of June 20, 1995 (60 FR 32160). The document was published with an error in the telephone number for CDRH Facts on Demand. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Marquita B. Steadman, Center for Devices and Radiological Health (HFZ–84), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–4765.

SUPPLEMENTARY INFORMATION: In FR Doc. 95–14947, appearing on page 32160 in the **Federal Register** of June 20, 1995, the following correction is made:

In the second column, under the **''Addresses''** caption, in line 20, the telephone number ''1–800–899–0281'' for CDRH Facts on Demand is corrected to read ''1–800–899–0381''.

Dated: August 17, 1995.

William K. Hubbard,

Acting Deputy Commissioner for Policy.

[FR Doc. 95–21095 Filed 8–24–95; 8:45 am]

BILLING CODE 4160–01–F

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made final findings of scientific misconduct in the following case:

Oscar R. Rosales, M.D., Yale University School of Medicine: On August 2, 1995, ORI found that Oscar R. Rosales, M.D., Assistant Professor of Medicine (Cardiology) at the Yale University School of Medicine, committed scientific misconduct by plagiarizing and intentionally misrepresenting research in an application for Public Health Service (PHS) funded research supported by grant application 1 R24 RR05358–01.

Dr. Rosales has entered into a Voluntary Settlement Agreement with ORI in which he has accepted ORI's finding and, for the three (3) year period beginning August 2, 1995, has voluntarily agreed to:

(1) exclude himself from serving in any advisory capacity to the PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and

(2) certify in every PHS research application or report that all contributors to the application or report are properly cited or otherwise acknowledged. This certification must be endorsed by an institutional official, and the institution must send a copy of the certification to ORI.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852.

Lyle W. Bivens,

Director, Office of Research Integrity.

[FR Doc. 95–21093 Filed 8–24–95; 8:45 am]

BILLING CODE 4160–17–P

Public Health Service

National Institutes of Health; Proposed Data Collection Available for Public Comment

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the National Institutes of Health (NIH), National Cancer Institute (NCI) will publish periodic summaries of proposed projects. To request more information on the proposed project, call Shelia Hoar Zahm, Sc.D., Epidemiologist, at (301) 496–9093.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including